Cover Image
市場調查報告書

主要已發展市場的緊急醫療藥物市場:開發後期及新4因子PCC(凝血酶原復合物濃縮劑)及重組產品所推動的市場

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

出版商 GBI Research 商品編碼 307934
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
主要已發展市場的緊急醫療藥物市場:開發後期及新4因子PCC(凝血酶原復合物濃縮劑)及重組產品所推動的市場 Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market
出版日期: 2014年07月14日 內容資訊: 英文
簡介

2013年主要的已開發市場急救市場規模推測為18億美金。預測今後將以4.7%的CAGR速度擴大,到2019年達到25億美金的規模。美國通過新的凝血因子濃縮劑的認証、預計今後將擴大引進這個因素推動該市場的成長。由於新的凝血因子濃縮劑在急救醫療現場和FFP及冷凍沈澱品等舊產品相比,感染風險低,因此需求量日益增加。

本報告調查主要已開發國家上急救醫療用藥物的市場,提供您主要的藥物種類與概要,已上市的主要產品及確實的開發平台階段產品概要,彙整主要的已開發國家/地區市場的市場成長預測,成長推進因素·阻礙要素分析,企業間的各種契約·聯盟趨勢等。

第1章 目錄

第2章 簡介

  • 緊急醫療的白蛋白
    • 概要
    • 適應症
    • 流行病學
    • 其他治療選擇
    • 治療模式
  • 緊急醫療的濃縮抗凝血酵素Ⅲ
    • 概要
    • 缺乏抗凝血酵素Ⅲ
    • 流行病學
    • 治療選擇
    • 治療模式
  • 緊急醫療的凝血因子XⅢ濃縮劑
    • 概要
    • 缺乏凝血因子XⅢ
    • 流行病學
    • 治療選擇
    • 治療模式
  • 緊急醫療的濃縮纖維蛋白原
    • 概要
    • 缺乏纖維蛋白原
    • 流行病學
    • 治療選擇
    • 治療模式
  • 緊急醫療的濃縮凝血素原複合體
    • 概要
    • 適應症
    • 流行病學
    • 治療選擇
    • 治療模式

第3章 目前藥物

  • 白蛋白產品
    • Buminate (人體血清蛋白): Baxter
    • Zenalb (人體血清蛋白):Bio Products Laboratory
    • Human Albumin Biotest (人體血清蛋白):Biotest
    • AlbuRx (白蛋白):CSL Behring
    • Albuminar (人體血清蛋白) 5%:CSL Behring
    • Albutein (人體血清蛋白):Grifols
    • Albuked (人體血清蛋白):Kedrion
    • Vialebex (人體血清蛋白):French Fractionation·Biotechnology Laboratory
    • Albunorm (人體血清蛋白):Octapharma
    • Alburaas (人體血清蛋白):Shanghai RAAS
  • 濃縮抗凝血酵素
    • Atryn (抗凝血酵素Alpha):rEVO Biologics
    • Thrombate Ⅲ (AT Ⅲ human):Grifols
    • Anbinex (AT Ⅲ human):Grifols
    • Kybernin P (AT Ⅲ human):CSL Behring
    • Aclotine (AT Ⅲ human):French Fractionation·Biotechnology Laboratory
    • Anti-Thrombin (AT Ⅲ human): Baxter
    • AT Ⅲ Kedrion (AT Ⅲ human):Kedrion
    • Neuart (AT Ⅲ human):田邊三菱製藥
  • 凝血因子XⅢ濃縮劑
    • Fibrogammin/Corifact (凝血因子XⅢ):CSL Behring
    • NovoThirteen/Tretten (catridecacog):Novo Nordisk
  • 濃縮纖維蛋白原
    • Haemocomplettan P/Riastap (濃縮人纖維蛋白原):CSL Behring
    • Clottafact/Clottagen (濃縮人纖維蛋白原):French Fractionation·Biotechnology Laboratory
    • 其他已上市濃縮纖維蛋白原
  • 濃縮凝血素原複合體
    • Beriplex P/N/Confidex/Kcentra (濃縮人凝血素原複合體):CSL Behring
    • Bebulin VH (第九凝血因子複合體, 蒸熱): Baxter
    • Cofact (濃縮凝血素原複合體):Sanquin
    • Octaplex 500 (人凝血素原複合體):Octapharma
    • Profilnine SD:Grifols
    • Uman Complex DI:Kedrion

第4章 緊急醫療針對市場的開發平台

  • 概要
  • 確實的開發平台候補藥
    • Octaplex 500 (人凝血素原複合體):Octapharma
    • KW-3357:Kyowa Hakko Kirin
    • Human AT Concentrate:Grifols

第5章 緊急醫療市場預測

  • 地區市場
    • 主要的已發展市場
    • 美國
    • 歐洲主要5個國家
    • 日本
    • 加拿大
  • 成長推進因素·阻礙要素
    • 成長推進因素
    • 阻礙成長要素

第6章 各種契約·策略性整合

  • 大型契約

第7章 附錄:緊急醫療市場預測

  • 簡稱
  • 索引
  • 開發中產品
  • 市場預測
  • 調查手法等

圖表

目錄
Product Code: GBIHC335MR

GBI Research, the leading business intelligence provider, has released its latest research: "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market", which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.The report includes -

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
  • Multi-scenario forecasts of the critical care market over the 2013-2020 period in the eight major developed markets
  • Key drivers and restraints that have had and are expected to have a significant impact on the market
  • An overview of major licensing and co-development agreements that could affect growth trends

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to markets with high growth potential
  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Critical Care Market to Reach $2.5 Billion in the Major Developed Markets by 2020

The critical care market in the eight major developed markets (the US, UK, France, Germany, Italy, Spain, Japan and Canada) was worth an estimated $1.8 billion in 2013 and is expected to grow to $2.5 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 4.7%. The majority of this revenue was due to albumin sales which amounted to $1.1 billion in 2013 and are expected to grow to $1.6 billion by 2020. In terms of markets, the US held the largest share with 41% of the total critical care market in 2013 and is projected to grow at the highest rate of any market at 7.5% during the 2013-2020 period.

Albumin was used to treat the highest share of the critical care treatment population across all eight markets with 2.2 million patients of a total of 2.4 million in 2013. Expectedly, the highest share of these patients was in the US, a total of 46% in 2013. A further 39.3% of the 2013 treatment population were located in the top five countries of Europe, followed by Japan with 9.5% and rest from Canada. The treatment population in the US is estimated to grow at a CAGR of 0.9% until 2020 with highest growth expected in the number of patients treated with Prothrombin Complex Concentrate (PCC) which is expected to grow at a CAGR of 2%. Globally, the treatment population receiving Anti-Thrombin (AT) concentrates and PCCs is expected to be larger than any other category and will grow at a CAGR of 1.5% during the 2013-2020 period.

The projected high growth rate of revenues in the US market of 7.5% is mainly due the increased uptake of factor concentrates over older alternatives (such as Fresh-Frozen Plasma (FFP)), higher price inflation and the launch of new drugs such as Kcentra (PPC, human) and Tretten (Factor XIII concentrate, recombinant) in 2013. Kcentra is the first four-factor PCC in the US and Tretten is the first recombinant factor XIII concentrate. In the top five European critical care markets there have been no recent significant product launches and none are expected during the forecast period. These markets are therefore anticipated to grow slowly during the forecast period, the UK market will grow at a CAGR of 3.0%, followed by France at 2.5%, Germany and Spain will each grow at 2.3% and Italy at 2.0%.

Increased Uptake of Four-Factor Prothombin Complex Concentrates in the US will Boost Growth

Although four-factor PCCs have been available in the European Union (EU) since 1996 , Kcentra became the first four-factor PCC to be approved in the US in 2013. Kcentra is a non-activated four-factor PCC which contains the vitamin K-dependent coagulation factors II, VII, IX, and X and antithrombotic proteins C and S. It is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g. warfarin) therapy. In the US 35-40 million prescriptions of warfarin are dispensed each year and the incidence of fatal bleeding in patients on this treatment is 1-3%. Kcentra is already available in other markets such as Europe and Australia under the brand names Beriplex and/or Confidex and was first approved in Europe in 2008. Kcentra has been awarded new technology add-on payment status by the Centers for Medicare and Medicaid Services which grants additional reimbursement for inpatient costs under Medicare. Another four-factor PCC from Octapharma is in late-stage development in the US and is expected to be launched in late 2014 which will present another four-factor PCC option for clinicians. As the US has a large patient pool and a higher cost of therapy than other markets, the launch of these new four-factor PCCs is expected to give a tremendous boost to the PCC market during the forecast period.

Recombinant Factor Concentrates to Witness Strong Uptake

The use of factor concentrates is relatively recent in the US where vitamin K, FFP or cryoprecipitate were the traditionally preferred options in most critical care settings covered in this report. For example, although off-label use of three-factor PCCs and recombinant Factor (F) VII is prevalent, vitamin K and plasma were the recommended options for vitamin K antagonist reversal in the US. With the recent approval of several new factor concentrates in the US, the critical care market landscape is expected to change drastically. For congenital factor deficiencies, availability of more concentrated forms of the required factors in factor concentrates is much more efficacious and less risky than FFP treatment as factor concentrates are subjected to a viral inactivation process. However, recent recombinant products present a much better safety profile as they are not blood- or plasma-derived products and therefore completely avoid any related risks. While factor concentrates are established treatments in the EU, recombinant products are relatively new. Atryn (AT concentrate, recombinant) and NovoThirteen (or Tretten) are two recombinant products that expected to gain a good share of their respective markets in both the US and EU. Atryn, a recombinant AT concentrate, was approved in the US in 2009 and Tretten, a recombinant FXIII concentrate, in 2013.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Albumin in Critical Care
    • 2.1.1. Overview
    • 2.1.2. Diseases or Conditions Indicated for Albumin
    • 2.1.3. Epidemiology
    • 2.1.4. Other Treatment Options
    • 2.1.5. Treatment Patterns
  • 2.2. Anti-Thrombin III Concentrates in Critical Care
    • 2.2.1. Overview
    • 2.2.2. Anti-Thrombin Deficiencies
    • 2.2.3. Epidemiology
    • 2.2.4. Treatment Options
    • 2.2.5. Treatment Patterns
  • 2.3. Factor XIII Concentrates in Critical Care
    • 2.3.1. Overview
    • 2.3.2. FXIII Deficiencies
    • 2.3.3. Epidemiology
    • 2.3.4. Treatment Options
    • 2.3.5. Treatment Patterns
  • 2.4. Fibrinogen Concentrates in Critical Care
    • 2.4.1. Overview
    • 2.4.2. Fibrinogen Deficiencies
    • 2.4.3. Epidemiology
    • 2.4.4. Treatment Options
    • 2.4.5. Treatment Patterns
  • 2.5. Prothrombin Complex Concentrate in Critical Care
    • 2.5.1. Overview
    • 2.5.2. Diseases or Conditions Indicated for Prothrombin Complex Concentrate
    • 2.5.3. Epidemiology
    • 2.5.4. Treatment Options
    • 2.5.5. Treatment Patterns

3. Therapeutic Landscape

  • 3.1. Albumin Products
    • 3.1.1. Buminate (albumin, human) - Baxter
    • 3.1.2. Zenalb (human albumin) - Bio Products Laboratory
    • 3.1.3. Human Albumin Biotest (albumin, human) - Biotest
    • 3.1.4. AlbuRx (albumin) - CSL Behring
    • 3.1.5. Albuminar (albumin, human) 5% - CSL Behring
    • 3.1.6. Albutein (albumin (human)) - Grifols
    • 3.1.7. Albuked (human albumin) - Kedrion
    • 3.1.8. Vialebex (human albumin) - French Fractionation and Biotechnology Laboratory
    • 3.1.9. Albunorm (human albumin) - Octapharma
    • 3.1.10. Alburaas (human albumin) - Shanghai RAAS
  • 3.2. Anti-Thrombin Concentrates
    • 3.2.1. Atryn (antithrombin alfa) - rEVO Biologics
    • 3.2.2. Thrombate III (AT III human) - Grifols
    • 3.2.3. Anbinex (AT III human) - Grifols
    • 3.2.4. Kybernin P (AT III human) - CSL Behring
    • 3.2.5. Aclotine (AT III, human) - French Fractionation and Biotechnology Laboratory
    • 3.2.6. Anti-Thrombin III (AT III human) - Baxter
    • 3.2.7. AT III Kedrion (AT III human) - Kedrion
    • 3.2.8. Neuart (AT III, human) - Mitsubishi Tanabe
  • 3.3. Factor XIII Concentrates
    • 3.3.1. Fibrogammin/Corifact (factor XIII) - CSL Behring
    • 3.3.2. NovoThirteen/Tretten (catridecacog) - Novo Nordisk
  • 3.4. Fibrinogen Concentrates
    • 3.4.1. Haemocomplettan P/Riastap (fibrinogen concentrate, human) - CSL Behring
    • 3.4.2. Clottafact/Clottagen (fibrinogen concentrate, human) - French Fractionation and Biotechnology Laboratory
    • 3.4.3. Other Marketed Fibrinogen Concentrates
  • 3.5. Prothrombin Complex Concentrates
    • 3.5.1. Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) - CSL Behring
    • 3.5.2. Bebulin VH (factor IX complex, vapor heated) - Baxter
    • 3.5.3. Cofact (prothrombin complex concentrate) - Sanquin
    • 3.5.4. Octaplex 500 (human prothrombin complex) - Octapharma
    • 3.5.5. Profilnine SD - Grifols
    • 3.5.6. Uman Complex DI - Kedrion

4. Pipeline for Critical Care Market

  • 4.1. Overview of Pipeline
  • 4.2. Promising Pipeline Candidates
    • 4.2.1. Octaplex 500 (human prothrombin complex) - Octapharma
    • 4.2.2. KW-3357- Kyowa Hakko Kirin
    • 4.2.3. Human AT Concentrate - Grifols

5. Critical Care Market Forecast to 2020

  • 5.1. Geographical Markets
    • 5.1.1. Major Developed Markets
    • 5.1.2. US
    • 5.1.3. Top Five European Countries
    • 5.1.4. Japan
    • 5.1.5. Canada
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Deals
    • 6.1.1. Octapharma Enters Into an Agreement with Pfizer
    • 6.1.2. Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis
    • 6.1.3. Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Korea-based Bio-pharmaceutical Joint Venture
    • 6.1.4. Bain Capital Acquires 80% Stake in Plasma Resources UK
    • 6.1.5. Biomat Acquires Three Plasma Donation Centers from Cangene
    • 6.1.6. BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact
    • 6.1.7. Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
    • 6.1.8. Shire Enters into Licensing Agreement with Sangamo BioSciences
    • 6.1.9. Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma

7. Critical Care Market to 2020 - Appendix

  • 7.1. Abbreviations
  • 7.2. References
  • 7.3. Pipeline Products
  • 7.4. Market Forecasts to 2020
    • 7.4.1. Major Developed Markets
    • 7.4.2. US
    • 7.4.3. UK
    • 7.4.4. France
    • 7.4.5. Germany
    • 7.4.6. Italy
    • 7.4.7. Spain
    • 7.4.8. Japan
    • 7.4.9. Canada
  • 7.5. Research Methodology
    • 7.5.1. Coverage
    • 7.5.2. Secondary Research
    • 7.5.3. Primary Research
    • 7.5.4. Therapeutic Landscape
    • 7.5.5. Geographical Landscape
    • 7.5.6. Pipeline Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Critical Care Market, Atryn, Development Timeline, 2007-2013
  • Table 2: Critical Care Market, Global, Pharmaceutical Pipeline, 2014
  • Table 3: Critical Care Market, Major Developed Markets, Market Forecast, 2013-2020
  • Table 4: Critical Care Market, Major Developed Markets, Albumin, Market Forecast, 2013-2020
  • Table 5: Critical Care Market, Major Developed Markets, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 6: Critical Care Market, Major Developed Markets, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 7: Critical Care Market, Major Developed Markets, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 8: Critical Care Market, Major Developed Markets, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 9: Critical Care Market, US, Market Forecast, 2013-2020
  • Table 10: Critical Care Market, US, Albumin, Market Forecast, 2013-2020
  • Table 11: Critical Care Market, US, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 12: Critical Care Market, US, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 13: Critical Care Market, US, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 14: Critical Care Market, US, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 15: Critical Care Market, UK, Market Forecast, 2013-2020
  • Table 16: Critical Care Market, UK, Albumin, Market Forecast, 2013-2020
  • Table 17: Critical Care Market, UK, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 18: Critical Care Market, UK, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 19: Critical Care Market, UK, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 20: Critical Care Market, UK, Market Forecast, Prothrombin Complex Concentrates, 2013-2020
  • Table 21: Critical Care Market, France, Market Forecast, 2013-2020
  • Table 22: Critical Care Market, France, Albumin, Market Forecast, 2013-2020
  • Table 23: Critical Care Market, France, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 24: Critical Care Market, France, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 25: Critical Care Market, France, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 26: Critical Care Market, France, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 27: Critical Care Market, Germany, Market Forecast, 2013-2020
  • Table 28: Critical Care Market, Germany, Albumin, Market Forecast, 2013-2020
  • Table 29: Critical Care Market, Germany, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 30: Critical Care Market, Germany, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 31: Critical Care Market, Germany, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 32: Critical Care Market, Germany, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 33: Critical Care Market, Italy, Market Forecast, 2013-2020
  • Table 34: Critical Care Market, Italy, Albumin, Market Forecast, 2013-2020
  • Table 35: Critical Care Market, Italy, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 36: Critical Care Market, Italy, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 37: Critical Care Market, Italy, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 38: Critical Care Market, Italy, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 39: Critical Care Market, Spain, Market Forecast, 2013-2020
  • Table 40: Critical Care Market, Spain, Albumin, Market Forecast, 2013-2020
  • Table 41: Critical Care Market, Spain, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 42: Critical Care Market, Spain, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 43: Critical Care Market, Spain, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 44: Critical Care Market, Spain, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 45: Critical Care Market, Japan, Market Forecast, 2013-2020
  • Table 46: Critical Care Market, Japan, Albumin, Market Forecast, 2013-2020
  • Table 47: Critical Care Market, Japan, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 48: Critical Care Market, Japan, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 49: Critical Care Market, Japan, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 50: Critical Care Market, Japan, Prothrombin Complex Concentrates, Market Forecast, 2013-2020
  • Table 51: Critical Care Market, Canada, Market Forecast, 2013-2020
  • Table 52: Critical Care Market, Canada, Albumin, Market Forecast, 2013-2020
  • Table 53: Critical Care Market, Canada, Anti-Thrombin Concentrates, Market Forecast, 2013-2020
  • Table 54: Critical Care Market, Canada, FXIII Concentrates, Market Forecast, 2013-2020
  • Table 55: Critical Care Market, Canada, Fibrinogen Concentrates, Market Forecast, 2013-2020
  • Table 56: Critical Care Market, Canada, Prothrombin Complex Concentrates, Market Forecast, 2013-2020

List of Figures

  • Figure 1: Critical Care Market, Global, Overall Pipeline Analysis (%), 2013
  • Figure 2: Critical Care Market, Major Developed Markets, Treatment Use Patterns, 2013-2020
  • Figure 3: Critical Care Market, Major Developed Markets, Revenue ($bn), 2013-2020
  • Figure 4: Critical Care Market, US, Treatment Use Patterns, 2013-2020
  • Figure 5: Critical Care Market, US, Annual Cost of Therapy and Revenue, 2013-2020
  • Figure 6: Critical Care Market, Top Five European Countries, Treatment Use Patterns, 2013 and 2020
  • Figure 7: Critical Care Market, Top Five European Countries, Annual Cost of Therapy ($), 2013-2020
  • Figure 8: Critical Care Market, Top Five European Countries, Revenue ($m), 2013-2020
  • Figure 9: Critical Care Market, Japan, Treatment Use Patterns, 2013-2020
  • Figure 10: Critical Care Market, Japan, Annual Cost of Therapy and Revenue, 2013-2020
  • Figure 11: Critical Care Market, Canada, Treatment Use Patterns, 2013-2020
  • Figure 12: Critical Care Market, Canada, Annual Cost of Therapy and Revenue, 2013-2020
  • Figure 13: GBI Research Market Forecasting Model
Back to Top